Arzneiwerk AG VIDA

As of December 31, 2024, Arzneiwerk AG VIDA has 6.23M shares outstanding.

These figures are as of December 31, 2024. The price-to-sales ratio is 6.07, and the price-to-book ratio stands at -1.26.

These figures are as of December 31, 2024. The EV/Sales ratio of 6.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Arzneiwerk AG VIDA trades at an EV/FCF ratio of 104.62, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2024, Arzneiwerk AG VIDA maintains a current ratio of 0.38, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024. Return on assets (ROA) is negative at -22.36, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -7.71, pointing to unprofitable operations over the period.

These figures cover the twelve months ended December 31, 2024. That works out to an effective tax rate of 15.09, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

Over the twelve months ended December 31, 2024, Arzneiwerk AG VIDA posted a gross margin of 100.14, reflecting its pricing power and cost economics. The operating margin of -7.00 and net profit margin of -127.02 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2024. Free cash flow yield is negative at -33.57: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -36.42, meaning Arzneiwerk AG VIDA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Arzneiwerk AG VIDA's most recent stock split took place on July 10, 2020 with a 8:1 split ratio.

As of December 31, 2024, Arzneiwerk AG VIDA has an Altman Z-Score of -2.58, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.